The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

J. Bousquet; C. Bindslev-Jensen; G. W. Canonica; W. Fokkens; H. Kim; M. Kowalski; A. Magnan; J. Mullol; P. van Cauwenberge

doi:https://doi.org/10.1111/j.1398-9995.2004.00577.x

The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

J. Bousquet, C. Bindslev-Jensen, G. W. Canonica, W. Fokkens, H. Kim, M. Kowalski, A. Magnan, J. Mullol, P. van Cauwenberge

Ear, Nose and Throat (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

46 Citations (Scopus)

Abstract

Background: The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment Of allergic rhinitis. Methods: An international group of experts met to assess the profile of the under the ARIA/EAACI criteria. Data on desloratadine antihistamine, desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Results and conclusion: Based on this systematic review, it was concluded that the safety and pharmacology of desloratadine broadly meet the ARIA/efficacy, EAACI criteria for antihistamines

Original language	English
Pages (from-to)	4-16
Journal	Allergy
Volume	59
Issue number	Suppl. 77
DOIs	https://doi.org/10.1111/j.1398-9995.2004.00577.x
Publication status	Published - 2004

Access to Document

https://doi.org/10.1111/j.1398-9995.2004.00577.x

Cite this

@article{39c73935a4cc4fa2a01406f0c556b175,

title = "The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine",

abstract = "Background: The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment Of allergic rhinitis. Methods: An international group of experts met to assess the profile of the under the ARIA/EAACI criteria. Data on desloratadine antihistamine, desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Results and conclusion: Based on this systematic review, it was concluded that the safety and pharmacology of desloratadine broadly meet the ARIA/efficacy, EAACI criteria for antihistamines",

author = "J. Bousquet and C. Bindslev-Jensen and Canonica, {G. W.} and W. Fokkens and H. Kim and M. Kowalski and A. Magnan and J. Mullol and {van Cauwenberge}, P.",

year = "2004",

doi = "https://doi.org/10.1111/j.1398-9995.2004.00577.x",

language = "English",

volume = "59",

pages = "4--16",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "Suppl. 77",

}

TY - JOUR

T1 - The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

AU - Bousquet, J.

AU - Bindslev-Jensen, C.

AU - Canonica, G. W.

AU - Fokkens, W.

AU - Kim, H.

AU - Kowalski, M.

AU - Magnan, A.

AU - Mullol, J.

AU - van Cauwenberge, P.

PY - 2004

Y1 - 2004

N2 - Background: The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment Of allergic rhinitis. Methods: An international group of experts met to assess the profile of the under the ARIA/EAACI criteria. Data on desloratadine antihistamine, desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Results and conclusion: Based on this systematic review, it was concluded that the safety and pharmacology of desloratadine broadly meet the ARIA/efficacy, EAACI criteria for antihistamines

AB - Background: The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment Of allergic rhinitis. Methods: An international group of experts met to assess the profile of the under the ARIA/EAACI criteria. Data on desloratadine antihistamine, desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Results and conclusion: Based on this systematic review, it was concluded that the safety and pharmacology of desloratadine broadly meet the ARIA/efficacy, EAACI criteria for antihistamines

U2 - https://doi.org/10.1111/j.1398-9995.2004.00577.x

DO - https://doi.org/10.1111/j.1398-9995.2004.00577.x

M3 - Article

C2 - 15236647

SN - 0105-4538

VL - 59

SP - 4

EP - 16

JO - Allergy

JF - Allergy

IS - Suppl. 77

ER -